JINARC 15 mg + 45 mg COMPRIMIDOS

USDailyMed:Tolvaptan UK: Contraindicated C03XA01(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only N-(4-{[(5R)-7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-methylphenyl)-2-methylbenzamide 150683-30-0N 216237 2226 DB06212Y 187438Y 21G72T1950 D01213 CHEBI:32246 ChEMBL344159Y DTXSID3048780 Interactive image Cc1ccccc1C(=O)Nc2cc(C)c(cc2)C(=O)N3c4ccc(Cl)cc4[C@H](O)CCC3 InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)​‍​​​​​‍​‍‍‍‍​‍‍22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)YKey:GYHCTFXIZSNGJT-UHFFFAOYSA-NY Tolvaptan, sold under the brand nameSamscaamong others, is anaquareticdrug that functions as a selective,competitivevasopressin receptor 2 (V2) antagonistused to treathyponatremia(low bloodsodiumlevels) associated withcongestive heart failure,cirrhosis, and thesyndrome of inappropriate antidiuretic hormone(SIADH). Tolvaptan was approved by the U.S.Food and Drug Administration(FDA) on May 19, 2009, and is sold byOtsuka Pharmaceutical Co.under the trade name Samsca.Tolvaptan, as Jynarque, was granted approval for medical use in the United States in April 2018. The U.S.Food and Drug Administration(FDA) granted tolvaptan afast trackdesignation for clinical trials investigating its use for the treatment ofpolycystic kidney disease.The FDA granted Jynarque anorphan drugdesignation in April 2012, for the treatment ofautosomal dominant polycystic kidney disease. Tolvaptan is available as ageneric medication.